Celgene's Revlimid defenses withstand another challenge

A U.S. patent board declined to review key patents held by Celgene on its top-selling multiple myeloma drug Revlimid, denying petitions Monday from Indian drugmaker Dr. Reddy's that sought to begin a process to overturn them.